Omeros Corporation Announces Late-Breaking Presentation of OMS906 Data at the 2023 European Hematology Association (EHA) Congress
01 Junio 2023 - 10:00AM
Business Wire
– Late-breaking abstract detailing interim data
from ongoing clinical trial of OMS906 in treatment-naïve PNH
patients selected for June 11, 2023 oral presentation –
Omeros Corporation (Nasdaq: OMER) today announced that data from
a pre-specified interim analysis of its ongoing Phase 1b clinical
trial of OMS906, the company’s lead MASP-3 inhibitor, in
complement-inhibitor-naïve adults with paroxysmal nocturnal
hemoglobinuria (PNH), a rare and life-threatening hemolytic blood
disorder, will be shared at the 2023 European Hematology
Association (EHA) Congress in Frankfurt, Germany. Identified as one
of the top five late-breaking submissions by the Scientific Program
Committee, the abstract was selected for oral presentation.
The presentation, entitled OMS906, A mannan-binding
lectin-associated serine protease-3 (MASP-3) Inhibitor, Normalizes
Hemoglobin Levels in Treatment-naïve PNH Patients: Interim Data
from a Proof-of-Concept Clinical Trial, will be delivered by Jens
Panse, MD, Senior Physician and Deputy Director of the Department
of Hematology, Oncology, Hemostaseology and Stem Cell
Transplantation, University Hospital RWTH Aachen, and Managing
Medical Director of the Center for Integrated Oncology, Aachen,
Germany.
Dr. Panse’s presentation will be delivered at the late-breaking
oral session scheduled for 9:45-11:15 CEST on Sunday, June 11, 2023
and will be available by livestream to registered meeting attendees
via the congress platform. The presentation abstract (#LB2714) was
embargoed by EHA until 16:00 CEST today but now is freely
accessible on EHA’s website. Following Dr. Panse’s presentation,
Omeros will make available on its website the associated
slides.
Also at this EHA congress, Morag Griffin, MBChB, FRCPath,
Consultant in Haematology of St. James University Teaching
Hospital, Leeds, United Kingdom, will present a poster describing
findings from a single-ascending dose study evaluating OMS906
safety, pharmacokinetics and pharmacodynamics in healthy subjects.
Dr. Griffin’s presentation is scheduled for 18:00-19:00 CEST on
Friday, June 9, 2023 and will be available for viewing by
registered attendees on the online EHA platform throughout the
duration of the congress (June 8-11, 2023). The presentation
abstract (#P787) is available to everyone on EHA’s website.
About PNH
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare,
life-threatening acquired disorder that causes production of red
blood cells lacking certain surface proteins (CD55 and CD59),
making them vulnerable to destruction by the complement system.
This leads to intravascular hemolysis (destruction of red blood
cells within blood vessels) and extravascular hemolysis (when
damaged red blood cells are removed by macrophages in the spleen or
liver). Left untreated, PNH is associated with debilitating anemia,
a high risk of thrombosis, fatigue, and a severely reduced survival
rate. There remains a significant unmet need for PNH therapies, as
a large proportion of patients treated with C5 inhibitors continue
to experience hemolysis and approximately one third of them still
require red blood cell transfusions.
About OMS906
OMS906 is an investigational human monoclonal antibody targeting
mannan-binding lectin-associated serine protease-3 (MASP-3), the
key activator of the complement system’s alternative pathway. The
complement system plays a central role in inflammation and becomes
activated as a result of tissue damage or microbial infection.
Responsible for the conversion of pro-complement factor D to
complement factor D, MASP-3 is believed to be the premier target in
the alternative pathway – it has the lowest native circulating
level and low relative clearance compared to the other alternative
pathway proteins and, unlike C5 and C3 blockers, MASP-3 inhibition
leaves intact the lytic arm of the classical pathway, important for
fighting infection. Also, unlike other components of the
alternative pathway, MASP-3 is believed not to be an acute phase
reactant, which could provide a significant advantage to MASP-3
inhibitors, like OMS906, over other alternative pathway inhibitors.
MASP-3 inhibitors are thought to have preventive or therapeutic
effects across a broad range of diseases including paroxysmal
nocturnal hemoglobinuria (PNH), hemolytic uremic syndrome (HUS),
atypical HUS, traumatic brain injury, arthritis, wet age-related
macular degeneration, ischemia-reperfusion injury,
transplant-related complications and other immune-related
disorders. Through its growing and exclusive intellectual property
position, Omeros controls the use of MASP-3 inhibitors across a
wide range of alternative pathway-related and other diseases and
disorders.
About Omeros Corporation
Omeros is an innovative biopharmaceutical company committed to
discovering, developing and commercializing small-molecule and
protein therapeutics for large-market and orphan indications
targeting immunologic disorders including complement-mediated
diseases, cancers, and addictive and compulsive disorders. Omeros’
lead MASP-2 inhibitor narsoplimab targets the lectin pathway of
complement and is the subject of a biologics license application
pending before FDA for the treatment of hematopoietic stem cell
transplant-associated thrombotic microangiopathy (TA-TMA).
Narsoplimab is also in multiple late-stage clinical development
programs focused on other complement-mediated disorders, including
IgA nephropathy, COVID-19, and atypical hemolytic uremic syndrome.
Omeros’ long-acting MASP-2 inhibitor OMS1029 is currently in a
Phase 1 clinical trial. OMS906, Omeros’ inhibitor of MASP-3, the
key activator of the alternative pathway of complement, is
advancing across multiple clinical programs for alternative
pathway-related diseases, including paroxysmal nocturnal
hemoglobinuria (PNH) and complement 3 (C3) glomerulopathy. For more
information about Omeros and its programs, visit
www.omeros.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230601005810/en/
Jennifer Cook Williams Cook Williams Communications, Inc.
Investor and Media Relations ir@omeros.com
Omeros (NASDAQ:OMER)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Omeros (NASDAQ:OMER)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024